22:48:55 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-06 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-06-07 Ordinarie utdelning EXPRS2 0.00 SEK
2024-06-05 Årsstämma 2024
2024-05-16 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-25 Ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24 Årsstämma 2023
2023-05-16 Kvartalsrapport 2023-Q1
2023-03-23 Extra Bolagsstämma 2023
2023-02-09 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-27 Ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-09-23 Extra Bolagsstämma 2020
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24 Årsstämma 2018
2018-05-17 Kvartalsrapport 2018-Q1
2018-02-07 Bokslutskommuniké 2017
2017-11-30 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-06-01 Ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-04-19 Extra Bolagsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-08 Kvartalsrapport 2016-Q3
2016-08-31 Kvartalsrapport 2016-Q2

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
ExpreS2ion Biotech Holding är ett forsknings- och utvecklingsbaserat bolag som har en patenterad plattform inom bioteknisk proteinproduktion. Bolaget har sin egen utvecklingspipeline av vaccinkandidater inom COVID-19, bröstcancer, influensa och malaria. Dessutom har bolaget intäkter från försäljning av tillverkningstjänster och plattformslicenser. Bolaget startade 2010 och har sin verksamhet i DTU Forskerpark i Hørsholm.
2023-11-03 15:30:00

Hørsholm, Denmark, 3 November 2023 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the Conference on Vaccines R&D (6-8 November), BIO-EUROPE (6-8 November) and the Vaccines Summit (13-15 November).

By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company's website (https://expres2ionbio.com/meet-us-2/).

6-8 November 2023 | Conference on Vaccines Research & Development
Baltimore, Maryland, USA (Virtual)
Dr. Farshad Guirakhoo, Chief Scientific Officer, is invited to present "Preclinical proof of concept for a novel VLP-based vaccine candidate for treatment of HER2+ breast cancers." He will present virtually on 8 November 2023 from 13:40 to 14:00 EST. The full list of speakers (https://vaccines.unitedscientificgroup.org/speakers) and more information about the event can be found on the event website (https://vaccines.unitedscientificgroup.org/).

6-8 November 2023 | BIO-EUROPE
Munich, Germany (In-person)
Meet CEO Bent Frandsen at the industry's largest gathering of biopharma professionals in Europe. More information and registration are available at BIO-Europe's website (https://informaconnect.com/bioeurope/).

13-15 November 2023 | Vaccines Summit
Boston, MA (In-person)
CSO Dr. Farshad Guirakhoo is invited to present "Preclinical proof-of-concept studies of a novel human HER-2 virus-like particle as a vaccine candidate for human breast cancers." He will chair the session on Cancer Vaccines & Immunotherapy, including his own presentation, on 15 November 2023 from 11:00 to 12:00 EST. The full list of speakers (https://scientiameetings.com/conferences/vaccines/speakers) and more information about the event can be found on the event website (https://scientiameetings.com/conferences/vaccines/about-vaccines-summit-2023-conference.php).

To pre-arrange meetings at these events, please email ExpreS[2]ion at info@expres2ionbio.com.